Cargando…
β1 Integrins as Therapeutic Targets to Disrupt Hallmarks of Cancer
Integrins belong to a large family of αβ heterodimeric transmembrane proteins first recognized as adhesion molecules that bind to dedicated elements of the extracellular matrix and also to other surrounding cells. As important sensors of the cell microenvironment, they regulate numerous signaling pa...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4656837/ https://www.ncbi.nlm.nih.gov/pubmed/26635609 http://dx.doi.org/10.3389/fphar.2015.00279 |
_version_ | 1782402287103115264 |
---|---|
author | Blandin, Anne-Florence Renner, Guillaume Lehmann, Maxime Lelong-Rebel, Isabelle Martin, Sophie Dontenwill, Monique |
author_facet | Blandin, Anne-Florence Renner, Guillaume Lehmann, Maxime Lelong-Rebel, Isabelle Martin, Sophie Dontenwill, Monique |
author_sort | Blandin, Anne-Florence |
collection | PubMed |
description | Integrins belong to a large family of αβ heterodimeric transmembrane proteins first recognized as adhesion molecules that bind to dedicated elements of the extracellular matrix and also to other surrounding cells. As important sensors of the cell microenvironment, they regulate numerous signaling pathways in response to structural variations of the extracellular matrix. Biochemical and biomechanical cues provided by this matrix and transmitted to cells via integrins are critically modified in tumoral settings. Integrins repertoire are subjected to expression level modifications, in tumor cells, and in surrounding cancer-associated cells, implicated in tumor initiation and progression as well. As critical players in numerous cancer hallmarks, defined by Hanahan and Weinberg (2011), integrins represent pertinent therapeutic targets. We will briefly summarize here our current knowledge about integrin implications in those different hallmarks focusing primarily on β1 integrins. |
format | Online Article Text |
id | pubmed-4656837 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-46568372015-12-03 β1 Integrins as Therapeutic Targets to Disrupt Hallmarks of Cancer Blandin, Anne-Florence Renner, Guillaume Lehmann, Maxime Lelong-Rebel, Isabelle Martin, Sophie Dontenwill, Monique Front Pharmacol Pharmacology Integrins belong to a large family of αβ heterodimeric transmembrane proteins first recognized as adhesion molecules that bind to dedicated elements of the extracellular matrix and also to other surrounding cells. As important sensors of the cell microenvironment, they regulate numerous signaling pathways in response to structural variations of the extracellular matrix. Biochemical and biomechanical cues provided by this matrix and transmitted to cells via integrins are critically modified in tumoral settings. Integrins repertoire are subjected to expression level modifications, in tumor cells, and in surrounding cancer-associated cells, implicated in tumor initiation and progression as well. As critical players in numerous cancer hallmarks, defined by Hanahan and Weinberg (2011), integrins represent pertinent therapeutic targets. We will briefly summarize here our current knowledge about integrin implications in those different hallmarks focusing primarily on β1 integrins. Frontiers Media S.A. 2015-11-24 /pmc/articles/PMC4656837/ /pubmed/26635609 http://dx.doi.org/10.3389/fphar.2015.00279 Text en Copyright © 2015 Blandin, Renner, Lehmann, Lelong-Rebel, Martin and Dontenwill. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Blandin, Anne-Florence Renner, Guillaume Lehmann, Maxime Lelong-Rebel, Isabelle Martin, Sophie Dontenwill, Monique β1 Integrins as Therapeutic Targets to Disrupt Hallmarks of Cancer |
title | β1 Integrins as Therapeutic Targets to Disrupt Hallmarks of Cancer |
title_full | β1 Integrins as Therapeutic Targets to Disrupt Hallmarks of Cancer |
title_fullStr | β1 Integrins as Therapeutic Targets to Disrupt Hallmarks of Cancer |
title_full_unstemmed | β1 Integrins as Therapeutic Targets to Disrupt Hallmarks of Cancer |
title_short | β1 Integrins as Therapeutic Targets to Disrupt Hallmarks of Cancer |
title_sort | β1 integrins as therapeutic targets to disrupt hallmarks of cancer |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4656837/ https://www.ncbi.nlm.nih.gov/pubmed/26635609 http://dx.doi.org/10.3389/fphar.2015.00279 |
work_keys_str_mv | AT blandinanneflorence b1integrinsastherapeutictargetstodisrupthallmarksofcancer AT rennerguillaume b1integrinsastherapeutictargetstodisrupthallmarksofcancer AT lehmannmaxime b1integrinsastherapeutictargetstodisrupthallmarksofcancer AT lelongrebelisabelle b1integrinsastherapeutictargetstodisrupthallmarksofcancer AT martinsophie b1integrinsastherapeutictargetstodisrupthallmarksofcancer AT dontenwillmonique b1integrinsastherapeutictargetstodisrupthallmarksofcancer |